These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 1840297

  • 21. Role of the renin-angiotensin-aldosterone system in atrial fibrillation and cardiac remodeling.
    Healey JS, Morillo CA, Connolly SJ.
    Curr Opin Cardiol; 2005 Jan; 20(1):31-7. PubMed ID: 15596957
    [Abstract] [Full Text] [Related]

  • 22. AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction.
    Azadpour M, Lamas GA.
    Expert Rev Cardiovasc Ther; 2004 Nov; 2(6):891-902. PubMed ID: 15500434
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. [Angiotensin-converting enzyme inhibitors in patients with preserved left ventricular function: from EUROPA to PREAMI].
    Ferrari R, Papa K, Bernocchi P, Gimbatti OJ, Golcea SS, Bettini A, Ceconi C.
    Ital Heart J; 2005 Nov; 6 Suppl 7():24S-32S. PubMed ID: 16485514
    [Abstract] [Full Text] [Related]

  • 25. [Modification of hemodynamics by angiotensin converting enzyme inhibitors in heart failure].
    Ertl G, Gaudron P, Eilles C.
    Herz; 1990 Jun; 15(3):158-63. PubMed ID: 2198216
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Progress in angiotensin-converting enzyme inhibition in heart failure: rationale, mechanisms, and clinical responses.
    Dzau VJ, Creager MA.
    Cardiol Clin; 1989 Feb; 7(1):119-30. PubMed ID: 2650868
    [Abstract] [Full Text] [Related]

  • 28. Potential novel pharmacological therapies for myocardial remodelling.
    Landmesser U, Wollert KC, Drexler H.
    Cardiovasc Res; 2009 Feb 15; 81(3):519-27. PubMed ID: 19019834
    [Abstract] [Full Text] [Related]

  • 29. The extent of regional wall motion abnormalities identifies patients at risk of extensive left ventricular remodeling: implications for the design of post myocardial infarction trials.
    Zanolla L, Marino P, Golia G, Anselmi M, Zardini P, Borghi C, Ambrosioni E.
    G Ital Cardiol; 1999 Jan 15; 29(1):20-6. PubMed ID: 9987043
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. [Current aspects of ACE inhibitor therapy from the cardiologic viewpoint].
    Klein W, Eber B, Gasser R, Stoschitzky K, Schumacher M, Fruhwald FM, Zweiker R.
    Wien Med Wochenschr; 1996 Jan 15; 146(11):221-4. PubMed ID: 8928518
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Vasodilator therapy for congestive heart failure. Lessons from mortality trials.
    Groden DL.
    Arch Intern Med; 1993 Feb 22; 153(4):445-54. PubMed ID: 8435024
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Angiotensin-converting enzyme inhibition and ventricular remodeling after myocardial infarction.
    Pfeffer JM, Fischer TA, Pfeffer MA.
    Annu Rev Physiol; 1995 Feb 22; 57():805-26. PubMed ID: 7778884
    [No Abstract] [Full Text] [Related]

  • 40. [ACE inhibition: indications in mild heart failure and asymptomatic left ventricular dysfunction?].
    Riegger AJ.
    Verh Dtsch Ges Inn Med; 1991 Feb 22; 97():562-6. PubMed ID: 1808946
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.